BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 30387841)

  • 1. MicroRNA‑766 inhibits papillary thyroid cancer progression by directly targeting insulin receptor substrate 2 and regulating the PI3K/Akt pathway.
    Zhao J; Li Z; Chen Y; Zhang S; Guo L; Gao B; Jiang Y; Tian W; Hao S; Zhang X
    Int J Oncol; 2019 Jan; 54(1):315-325. PubMed ID: 30387841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
    Wu YC; Li SY; Jia YF
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
    Ma Y; Qin H; Cui Y
    Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.
    Chen Y; Hao SA; Jiang Y; Gao B; Tian WG; Zhang S; Guo LJ; Wang LL; Luo DL
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7989-7999. PubMed ID: 31599424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-30c-5p loss-induced PELI1 accumulation regulates cell proliferation and migration via activating PI3K/AKT pathway in papillary thyroid carcinoma.
    Zheng T; Zhou Y; Xu X; Qi X; Liu J; Pu Y; Zhang S; Gao X; Luo X; Li M; Wang X; Dong L; Wang Y; Mao C
    J Transl Med; 2022 Jan; 20(1):20. PubMed ID: 34991623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA TTN-AS1 facilitates tumorigenesis of papillary thyroid cancer through modulating the miR-153-3p/ZNRF2 axis.
    Cui Z; Luo Z; Lin Z; Shi L; Hong Y; Yan C
    J Gene Med; 2019 May; 21(5):e3083. PubMed ID: 30811764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
    Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
    Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-215 suppresses papillary thyroid cancer proliferation, migration, and invasion through the AKT/GSK-3β/Snail signaling by targeting ARFGEF1.
    Han J; Zhang M; Nie C; Jia J; Wang F; Yu J; Bi W; Liu B; Sheng R; He G; Kong L; Zheng L; Pang R; Ding Z; Chen L; Guan Q; Pan S; Meng X; Xu J; Liu L; Zhang J
    Cell Death Dis; 2019 Feb; 10(3):195. PubMed ID: 30814512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.
    Li R; Liu J; Li Q; Chen G; Yu X
    Tumour Biol; 2016 Mar; 37(3):3987-96. PubMed ID: 26482618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-126 inhibits papillary thyroid carcinoma growth by targeting LRP6.
    Wen Q; Zhao J; Bai L; Wang T; Zhang H; Ma Q
    Oncol Rep; 2015 Oct; 34(4):2202-10. PubMed ID: 26239517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
    Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
    Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA‑509 targets PAX6 to inhibit cell proliferation and invasion in papillary thyroid carcinoma.
    Zhang S; Wang Q; Li D; Huang B; Hou X; Wang D
    Mol Med Rep; 2019 Feb; 19(2):1403-1409. PubMed ID: 30569166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circ_0079558 promotes papillary thyroid cancer progression by binding to miR-26b-5p to activate MET/AKT signaling.
    Zheng H; Fu Q; Ma K; Shi S; Fu Y
    Endocr J; 2021 Nov; 68(11):1247-1266. PubMed ID: 34565758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway.
    Sun W; Qian K; Guo K; Chen L; Xiang J; Li D; Wu Y; Ji Q; Sun T; Wang Z
    Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):382-389. PubMed ID: 32227107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
    Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
    Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-511 inhibits malignant behaviors of breast cancer by directly targeting SOX9 and regulating the PI3K/Akt pathway.
    Zhao Y; Pang W; Yang N; Hao L; Wang L
    Int J Oncol; 2018 Dec; 53(6):2715-2726. PubMed ID: 30272349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-203 restrains epithelial-mesenchymal transition, invasion and migration of papillary thyroid cancer by downregulating AKT3.
    You A; Fu L; Li Y; Li X; You B
    Cell Cycle; 2020 May; 19(10):1105-1121. PubMed ID: 32308106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.
    Feng J; Zhou Q; Yi H; Ma S; Li D; Xu Y; Wang J; Yin S
    Cell Death Dis; 2019 Jun; 10(6):433. PubMed ID: 31160577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway.
    Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C
    J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-31 inhibits papillary thyroid carcinoma cell biological progression by directly targeting SOX11 and regulating epithelial-to-mesenchymal transition, ERK and Akt signaling pathways.
    Wang Y; Liu BG; Zhou CX
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5863-5873. PubMed ID: 31298337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.